[Distribution of CD8+CD28- T cells and CD3+CD56+ NKT cells in peripheral blood of patients with B-cell non-Hodgkin's lymphoma]

Ai Zheng. 2004 Nov;23(11 Suppl):1437-42.
[Article in Chinese]

Abstract

Background & objective: Patients with B-cell non-Hodgkin's lymphoma (B-NHL) usually have a poor immune response. CD8(+)CD28(-) T cells (Ts) and CD3(+)CD56(+) NKT cells (NKT) are new types of immune suppressor cells. This study was to analyze proportions and changes of them in peripheral blood of patients with B-NHL, explore their effects on immunosuppression of B-NHL, and the influnce factors, to provide reference for intervening in immune function of B-NHL patients.

Methods: Peripheral blood samples were got from 79 naive patients with B-NHL before treatment, and 25 healthy people, samples of 18 patients who got complete remission (CR) after 4-6 cycles of chemotherapy were collected either before chemotherapy or after CR. Proportions of Ts and NKT were analyzed by flow cytometry (FCM).

Results: Compared with control group, proportions of Ts, and NKT in peripheral blood of B-NHL patients before chemotherapy were (18.19+/-5.03)%, and (6.08+/-3.29)%, significantly higher than those of healthy people [(11.20+/-3.49)%, P< 0.01; (3.52+/-1.56)%, P< 0.01]. There were no significant differences of proportions of Ts among patients with B-NHL of different clinical stages (P >0.05), and different malignant grade (P >0.05), and between before treatment and after CR (P=0.55). No significant difference of proportions of NKT was found among patients with B-NHL of different clinical stages (P >0.05), and different malignant grade (P >0.05), and between before treatment and after CR (P=0.39).

Conclusion: Populations of Ts and NKT commonly increased in peripheral blood of patients with B-NHL, they may play roles in immunosuppression of B-NHL.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • CD28 Antigens / blood
  • CD3 Complex / blood*
  • CD56 Antigen / blood
  • CD8 Antigens / blood
  • CD8-Positive T-Lymphocytes / immunology*
  • Female
  • Humans
  • Killer Cells, Natural / immunology*
  • Lymphocyte Count
  • Lymphoma, B-Cell / drug therapy
  • Lymphoma, B-Cell / immunology*
  • Lymphoma, B-Cell / pathology
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Remission Induction

Substances

  • CD28 Antigens
  • CD3 Complex
  • CD56 Antigen
  • CD8 Antigens